TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease

被引:12
作者
Binukumar, B. K. [1 ]
Pant, Harish C. [1 ]
机构
[1] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA
关键词
cyclin-dependent kinase 5; Parkinson's disease; neurodegeneration; therapeutic target; TP5; TFP5/TP5; peptide; MPTP; CYCLIN-DEPENDENT KINASE-5; NIGROSTRIATAL DOPAMINERGIC-NEURONS; CDK5 ACTIVATOR P35; PROTEIN-KINASE; OXIDATIVE STRESS; CDC2-LIKE KINASE; ALPHA-SYNUCLEIN; MOTOR-NEURONS; LEWY BODIES; TAU-PROTEIN;
D O I
10.4103/1673-5374.182681
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cyclin-dependent kinase 5 (Cdk5) is a member of the serine-threonine kinase family of cyclin-dependent kinases. Cdk5 is critical to normal mammalian nervous system development and plays important regulatory roles in multiple cellular functions. Recent evidence indicates that Cdk5 is inappropriately activated in several neurodegenerative conditions, including Parkinson's disease (PD). PD is a chronic neurodegenerative disorder characterized by the loss of dopamine neurons in the substantia nigra, decreased striatal dopamine levels, and consequent extrapyramidal motor dysfunction. During neurotoxicity, p35 is cleaved to form p25. Binding of p25 with Cdk5 leads deregulation of Cdk5 resulting in number of neurodegenerative pathologies. To date, strategies to specifically inhibit Cdk5 hyperactivity have not been successful without affecting normal Cdk5 activity. Here we show that inhibition of p25/Cdk5 hyperactivation through TFP5/TP5, truncated 24-aa peptide derived from the Cdk5 activator p35 rescues nigrostriatal dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP/MPP+) in a mouse model of PD. TP5 peptide treatment also blocked dopamine depletion in the striatum and improved gait dysfunction after MPTP administration. The neuroprotective effect of TFP5/TP5 peptide is also associated with marked reduction in neuroinflammation and apoptosis. Here we show inhibition of Cdk5/p25-hyperactivation by TFP5/TP5 peptide, which identifies Cdk5/p25 as a potential therapeutic target to reduce neurodegeneration in PD.
引用
收藏
页码:698 / 701
页数:4
相关论文
共 40 条
[1]   Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease [J].
Alvira, D ;
Tajes, M ;
Verdaguer, E ;
Acuña-Castroviejo, D ;
Folch, J ;
Camins, A ;
Pallas, M .
JOURNAL OF PINEAL RESEARCH, 2006, 40 (03) :251-258
[2]   Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35 [J].
Amin, ND ;
Albers, W ;
Pant, HC .
JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 67 (03) :354-362
[3]   Phosphorylation of parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation [J].
Avraham, Eyal ;
Rott, Ruth ;
Liani, Esti ;
Szargel, Raymonde ;
Engelender, Simone .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (17) :12842-12850
[4]   Cyclin-dependent kinase-5 is associated with lipofuscin in motor neurones in amyotrophic lateral sclerosis [J].
Bajaj, NPS ;
Al-Sarraj, ST ;
Anderson, V ;
Kibble, M ;
Leigh, N ;
Miller, CCJ .
NEUROSCIENCE LETTERS, 1998, 245 (01) :45-48
[5]   Cyclin dependent kinase-5 (cdk-5) phosphorylates neurofilament heavy (NF-H) chain to generate epitopes for antibodies that label neurofilament accumulations in amyotrophic lateral sclerosis (ALS) and is present in affected motor neurones in ALS [J].
Bajaj, NPS ;
Al-Sarraj, ST ;
Leigh, PN ;
Anderson, V ;
Miller, CCJ .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1999, 23 (05) :833-850
[6]   Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson's disease [J].
Binukumar, B. K. ;
Shukla, Varsha ;
Amin, Niranjana D. ;
Grant, Philip ;
Bhaskar, M. ;
Skuntz, Susan ;
Steiner, Joseph ;
Pant, Harish C. .
MOLECULAR BIOLOGY OF THE CELL, 2015, 26 (24) :4478-4491
[7]  
BRION JP, 1995, AM J PATHOL, V147, P1465
[8]   Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation [J].
Chung, Young C. ;
Bok, Eugene ;
Huh, Sue H. ;
Park, Ju-Young ;
Yoon, Sung-Hwa ;
Kim, Sang R. ;
Kim, Yoon-Seong ;
Maeng, Sungho ;
Park, Sung Hyun ;
Jin, Byung K. .
JOURNAL OF IMMUNOLOGY, 2011, 187 (12) :6508-6517
[9]   Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinson's Disease [J].
Chung, Young C. ;
Kim, Sang R. ;
Jin, Byung K. .
JOURNAL OF IMMUNOLOGY, 2010, 185 (02) :1230-1237
[10]   Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition [J].
Croisier, Emilie ;
Moran, Linda B. ;
Dexter, David T. ;
Pearce, Ronald K. B. ;
Graeber, Manuel B. .
JOURNAL OF NEUROINFLAMMATION, 2005, 2 (1)